Triamcinolone Acetonide
( DrugBank: Triamcinolone, Triamcinolone acetonide / KEGG DRUG: Triamcinolone, Triamcinolone acetonide, Triamcinolone diacetate, Triamcinolone hexacetonide, Triamcinolone, Triamcinolone acetonide, Triamcinolone diacetate, Triamcinolone hexacetonide )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 35 | Pemphigus | 1 |
| 46 | Malignant rheumatoid arthritis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 56 | Behcet disease | 1 |
35. Pemphigus
Clinical trials : 130 / Drugs : 159 - (DrugBank : 46) / Drug target genes : 28 - Drug target pathways : 174
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
56. Behcet disease
Clinical trials : 110 / Drugs : 137 - (DrugBank : 40) / Drug target genes : 40 - Drug target pathways : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|